News Daily News Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab Michael O'Riordan February 05, 2025
News Daily News Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER Michael O'Riordan February 08, 2024
News Daily News No Safety Concerns Seen With Inclisiran in Large ORION Analysis Michael O'Riordan December 06, 2023
News Daily News Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA Todd Neale September 19, 2023
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Conference News ESC 2022 Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE Michael O'Riordan August 31, 2022
News Daily News Nonfatal MI Not a Death Surrogate in Cardiology: Meta-analysis Caitlin E. Cox October 27, 2021
News Conference News ESC 2021 No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER Michael O'Riordan September 02, 2021
News Conference News EAS 2021 For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short Michael O'Riordan June 03, 2021
News Conference News AHA 2020 Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol Michael O'Riordan November 12, 2020
News Daily News FOURIER Surveys Reassure About Cognitive Safety of Evolocumab Todd Neale May 06, 2020
News Daily News Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES Michael O'Riordan May 04, 2020
News Daily News Most Secondary Prevention Patients Are Eligible for Multiple Drugs Michael O'Riordan January 03, 2020
News Daily News Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES Michael O'Riordan August 26, 2019
News Conference News EAS 2019 Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis Michael O'Riordan May 28, 2019
News Daily News PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction Michael O'Riordan April 29, 2019
News Conference News AHA 2018 Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study Michael O'Riordan November 15, 2018
News Daily News Starting Low and Going Lower: Some Benefit to Very Low LDL Levels Michael O'Riordan August 02, 2018